SMMT Reclaims Its 200-Day Line After a 59% Slide — $16.40 Now Decides the FDA Run

Summit Therapeutics (SMMT) went from $29.23 to $12.07 — a 59% collapse — and spent most of the year trapped below its 200-day moving average. Just after noon on Wednesday it did something it hasn't done through this whole bear leg: it reclaimed that trendline on heavy volume and institutional-sized bids. As of 12:45 p.m. ET the stock trades at $16.58, up 13.6%, a full two average-daily-ranges worth of upside in a single session.

The reclaim is the whole story, and it runs through one number. Everything now rides on holding above $16.40.

The signal: this is not the same bounce

Every pullback in this bear market produced a dead-cat hop that failed at lower highs. Today trades differently. The move is roughly two times the stock's recent average true range, the RSI is a strong-but-not-exhausted 67, and shares are changing hands at about 1.3 times the normal pace by midday, with the session's turnover near 4% of the float. The technicals point one way: participation, not a fast-twitch squeeze on thin volume.

The flow backs it up. Block orders are net buyers by roughly $4 million on the day and large orders by another $1.1 million, while retail is roughly flat. That doesn't prove "smart money" — it proves the buyers getting the shares up are the accounts that can move price, not a Reddit pool piling into a fading move.

The setup has a clock attached. The 200-day line is a trendline, but this stock is also a binary FDA bet: a BLA for ivonescimab in EGFR-mutated lung cancer was accepted for filing in January, and the decision lands November 14. Days ago those results were published in . The chart is now re-pricing that uncertainty in the run-up — and it's doing it from a structural reclaim, not from a hope rally.

The line: what earns $16.40

The 200-day moving average sits at $16.41. Price is grinding just above it. That's the exact spot where the countless "buy the dip" attempts in this downtrend got stranded — it's the average cost of everyone who has held through the whole decline, and it has been rejection author for months.

Hold above $16.40 through the close and the reclaim is real, opening a path back into the supply band it lost — first up toward the mid-to-upper teens of the prior 2026 congestion, with the $29.23 high as the far wall.

The trap door is $15.52 — today's opening price, untouched all session so far. It's the edge of a gap that refuses to close. Lose it and close back under the 200-day line, and this stops being a reclaim and becomes a fakeout: sellers above, and everyone who bought this breakout trapped at the top of a bear-market range.

The map:

Scenario	Trigger	Path	Invalidation	Horizon
Reclaim holds	Hold $16.40+ into a close	Probe upper congestion, then the $20s	Daily close < $15.52	Into Nov 14 PDUFA
Reclaim fails	Lose $15.52, back under 200-day	Trap springs; retest the $14s	Reclaim zone lost	Same session-to-days

The asymmetry matters. From $16.58, the first real supply overhead is roughly 10-20% away, while the line that breaks the thesis is about 6% below. The reward path is longer than the distance to invalidation — the green light, not the red one, currently controls the setup.

What traders may be missing

The easy read says "it's still 43% below its high, just another bounce, ignore it." That framing mistakes the chart for the event. The bull traps of this bear market all failed on falling volume below a falling 200-day line. This one is clawing back above that line on expanding participation days before a catalyst, and the marginal buyers are block-size.

A stock does not need to retrace its whole decline to restructure a decision. It needs to reclaim the level that stopped every prior attempt in this leg — and it has just done that at the exact moment a binary regulatory verdict is approaching. The chart now says the burden of proof has flipped. Bears who shorted the bounce are pressing just above $16.40, and they're the trapped inventory if the reclaim holds into the FDA run.

For the reader, this is a watchlist-level event, not a directive. The discipline is binary and it happens on the close: hold $16.40 and the reclaim stands; lose $15.52 and the trap springs. Right now, the level that decides the setup is in the buyers' hands.